Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Hematology

What is a DDAVP Challenge Test for Von Willebrand Disease?

At a Glance

A DDAVP challenge test is a diagnostic procedure that checks if your body responds to desmopressin by releasing enough clotting factors to stop a bleed. It helps doctors determine if DDAVP will be an effective treatment for your Von Willebrand Disease during future emergencies or surgeries.

In this answer

3 sections

01

Why Do I Need This Test?

02

What to Expect During the Procedure

03

Understanding Your Results

A DDAVP challenge test is a diagnostic procedure used to see if your body responds to a medication called desmopressin (DDAVP) by releasing stored von Willebrand factor (VWF) and Factor VIII into your bloodstream [1][2]. The purpose of this test is to help your care team determine if DDAVP will be an effective treatment for you in the event of a future emergency, minor surgery, or bleeding episode [3][4]. By performing this test when you are healthy and stable, your doctors will know exactly what therapies to rely on when you actually need them [5][6].

Why Do I Need This Test?

Even among people with the same type of Von Willebrand Disease (VWD), individual responses to DDAVP can vary widely [3][7]. Your body may release enough clotting factors to stop a bleed, or it may not [8]. A challenge test is the only way to confirm your body’s specific response before relying on the drug for clinical management [3].

DDAVP is most commonly effective for people with Type 1 VWD, which involves a partial deficiency of VWF [9][10]. However, it is generally ineffective for Type 3 VWD [11]. For those with other subtypes, such as Types 2A, 2M, and 2N, the response is heterogeneous and can vary, making the challenge test essential to see if it will work for you [3][12]. Conversely, for those with Type 2B VWD, DDAVP is often not recommended because it can cause your body to release an abnormal form of VWF that binds too tightly to platelets, potentially lowering your platelet count (thrombocytopenia) and worsening bleeding symptoms [13][14].

What to Expect During the Procedure

The DDAVP challenge test is usually performed in an outpatient clinic and takes a few hours. Because you will be waiting between blood draws, consider bringing a book, tablet, or work to pass the time. The clinic staff will follow a strict schedule for giving the medication and drawing your blood [5].

  1. Baseline Blood Draw: First, a nurse will take a blood sample to measure your resting levels of VWF and Factor VIII [6][15].
  2. Medication Administration: You will receive a dose of DDAVP. This is typically given either through an intravenous (IV) line, an injection under the skin (subcutaneous), or as a nasal spray [1].
  3. Follow-Up Blood Draws: After receiving the medication, the care team will draw your blood again at specific intervals—often 1 to 2 hours after the dose—to measure how much your VWF and Factor VIII levels have risen [16][17]. Some clinics may also perform a later blood draw (for example, at 4 hours) to evaluate the duration of your response and how quickly the clotting factors leave your body [8].
  4. Fluid Restriction: DDAVP can cause your body to retain water, which may lead to hyponatremia (dangerously low sodium levels in your blood) [18][19]. To prevent this, your care team will likely ask you to restrict how much liquid you drink during the test and for up to 24 hours afterward [20][21]. Strictly following this fluid restriction is essential to prevent severe hyponatremia, which carries rare but serious risks such as seizures [18][22]. Note that DDAVP is generally avoided in children under 2 years old due to a heightened risk of severe fluid retention and electrolyte imbalances [18][23].

While the test is generally safe, common mild side effects include facial flushing, mild temporary headaches, and minor changes in blood pressure [18][19]. However, if you experience symptoms like a severe headache or confusion—which can be warning signs of severe hyponatremia—seek emergency medical care immediately [18][19].

Understanding Your Results

After the lab processes your blood samples, your doctor will categorize you as a “responder” or a “non-responder” based on whether your factor levels increased enough to stop bleeding [5][21].

  • If you are a responder: DDAVP can be added to your medical chart as a safe, non-transfusion treatment option for minor surgeries, dental work, or bleeding episodes [1][2].
  • If you are a non-responder: Your doctor will know that DDAVP is not the right choice for you [24]. Instead, your care team will use alternative treatments, such as therapies that directly replace the missing clotting factors (VWF concentrates), to manage your bleeding when needed [25][26].

Common questions in this guide

Can You Develop Von Willebrand Disease Later in Life?Can You Get an Epidural with Von Willebrand Disease?Can You Have Iron Deficiency Without Anemia in VWD?Can You Play Sports with Von Willebrand Disease?Does Stress Affect Von Willebrand Disease Test Results?How Do Antifibrinolytics Work for VWD Bleeding?How Does Type O Blood Affect Von Willebrand Disease?How Is Von Willebrand Disease Inherited?Dental Work with Von Willebrand Disease: How to PrepareIs an IUD Safe for Women with Von Willebrand Disease?What Causes Delayed Postpartum Hemorrhage in VWD?What Is a Heavy Period with Von Willebrand Disease?Low VWF vs. Type 1 VWD: What is the Difference?Type 2N VWD vs. Hemophilia A: What's the Difference?Does Von Willebrand Disease Affect Life Expectancy?What Pain Meds Are Safe for Von Willebrand Disease?What's in a VWD Emergency Travel Letter?When Are Nosebleeds a Sign of Von Willebrand Disease?Why Must I Restrict Fluids After DDAVP?
What is the purpose of a DDAVP challenge test?
The test determines if your body responds to the medication desmopressin (DDAVP) by releasing enough stored clotting factors into your bloodstream. This helps your care team know if DDAVP will be an effective treatment for you during future bleeding episodes or minor surgeries.
How is the DDAVP challenge test performed?
You will first have a baseline blood draw, followed by a dose of DDAVP given through an IV, a subcutaneous injection, or a nasal spray. Your care team will draw your blood again after one to two hours to see how much your clotting factor levels have increased.
Why do I need to restrict my fluids after a DDAVP test?
DDAVP causes your body to retain water, which can lead to dangerously low sodium levels in your blood, known as hyponatremia. Restricting your fluid intake for up to 24 hours after the test is critical to prevent severe complications such as seizures.
What happens if I am a non-responder to DDAVP?
If your clotting factor levels do not rise enough during the test, you are considered a non-responder. Your doctor will then know to use alternative therapies, such as von Willebrand factor concentrates, to manage your bleeding when needed instead of DDAVP.
What are the side effects of a DDAVP challenge test?
Mild side effects are common and include facial flushing, temporary headaches, and minor changes in blood pressure. However, if you experience a severe headache or confusion, seek emergency medical care immediately, as these can be warning signs of severe sodium imbalance.

Questions for Your Doctor

5 questions

  • •Do I need to pause any of my current medications, such as hormonal birth control, before the test?
  • •Are there any specific fasting guidelines I need to follow before I arrive?
  • •What is my exact fluid limit in ounces for the 24 hours following the test?
  • •How long will it take to get the results of my challenge test back?
  • •Should I plan to have someone drive me home after the procedure?

Questions for You

4 questions

  • •What is my specific subtype of Von Willebrand Disease (e.g., Type 1, 2A, 2B, 2M, 2N, or 3)?
  • •Do I have any upcoming surgeries or dental procedures that this test will help me prepare for?
  • •Have I ever experienced severe headaches or known kidney issues that I should discuss with my doctor before the test?
  • •What side effects, if any, am I most concerned about managing after the procedure?

References

References (26)
  1. 1

    A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?

    Reardon B, Pasalic L, Favaloro EJ

    Biomolecules 2025; (15(7)) doi:10.3390/biom15070967.

    PMID: 40723839
  2. 2

    How I treat von Willebrand disease.

    Castaman G

    Thrombosis research 2020; (196()):618-625 doi:10.1016/j.thromres.2020.07.051.

    PMID: 32819724
  3. 3

    Desmopressin testing in von Willebrand disease: Lowering the burden.

    Heijdra JM, Atiq F, Al Arashi W, et al.

    Research and practice in thrombosis and haemostasis 2022; (6(6)):e12784 doi:10.1002/rth2.12784.

    PMID: 36186107
  4. 4

    Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review.

    Beltran A, Jaramillo AP, Vallejo MP, et al.

    Cureus 2023; (15(8)):e44310 doi:10.7759/cureus.44310.

    PMID: 37649925
  5. 5

    Improving 1-Deamino-8-D-Arginine Vasopressin (DDAVP) Challenges in Pediatric/Young Adult Patients With Bleeding Disorders: A Quality Improvement Study.

    Hallam M, Pruett A, Biega C, et al.

    Journal of pediatric hematology/oncology nursing 2024; (41(4)):292-297 doi:10.1177/27527530241246260.

    PMID: 39118317
  6. 6

    Haemostasis and beyond: The expanding role of desmopressin in intensive care.

    Vinjamuri S, Tiwari E, Kataria S, Juneja D

    World journal of critical care medicine 2025; (14(4)):108370 doi:10.5492/wjccm.v14.i4.108370.

    PMID: 41377554
  7. 7

    Desmopressin stimulation testing: Response to intravenous and intranasal forms.

    McCormick MC, Siripong N, Cooper JD

    Haemophilia : the official journal of the World Federation of Hemophilia 2018; (24(4)):e194-e198 doi:10.1111/hae.13452.

    PMID: 29578274
  8. 8

    von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.

    Atiq F, Schütte LM, Looijen AEM, et al.

    Blood advances 2019; (3(24)):4147-4154 doi:10.1182/bloodadvances.2019000863.

    PMID: 31834934
  9. 9

    Efficacy of adjusted weight-based dosing of desmopressin (1-deamino-8-d-arginine vasopressin in type 1 von Willebrand disease.

    Seaman CD

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2023; (34(7)):462-464 doi:10.1097/MBC.0000000000001251.

    PMID: 37823430
  10. 10

    How I treat type 2B von Willebrand disease.

    Kruse-Jarres R, Johnsen JM

    Blood 2018; (131(12)):1292-1300 doi:10.1182/blood-2017-06-742692.

    PMID: 29378695
  11. 11

    Von Willebrand's Disease.

    Mannucci PM, Franchini M

    The New England journal of medicine 2017; (376(7)):701 doi:10.1056/NEJMc1616060.

    PMID: 28207207
  12. 12

    Variants p.Pro2063Ser and p.Arg324* co-segregate in type 3 von Willebrand disease patients from Southern Brazil.

    Ornaghi AP, Meireles MR, Botton MR, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(2)):e204-e213 doi:10.1111/hae.14254.

    PMID: 33550700
  13. 13

    ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

    James PD, Connell NT, Ameer B, et al.

    Blood advances 2021; (5(1)):280-300 doi:10.1182/bloodadvances.2020003265.

    PMID: 33570651
  14. 14

    Laboratory variability in the diagnosis of type 2 VWD variants.

    DiGiandomenico S, Christopherson PA, Haberichter SL, et al.

    Journal of thrombosis and haemostasis : JTH 2021; (19(1)):131-138 doi:10.1111/jth.15129.

    PMID: 33049112
  15. 15

    Role of Desmopressin in Bleeding Disorders: What Indian Physicians Need to Know?

    Malve H, Goswami P, Asalkar A, More D

    The Journal of the Association of Physicians of India 2025; (73(1)):58-60 doi:10.59556/japi.73.0796.

    PMID: 39893530
  16. 16

    Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.

    Guddati AK, Rosovsky RP, Van Cott EM, Kuter DJ

    International journal of laboratory hematology 2019; (41(3)):325-330 doi:10.1111/ijlh.12978.

    PMID: 30735311
  17. 17

    Plasma proteomics in patients with von Willebrand disease and hemophilia A highlights von Willebrand factor as main determinant of response to desmopressin treatment.

    Alferez JDC, Smit ER, Meijer AB, et al.

    Research and practice in thrombosis and haemostasis 2025; (9(3)):102738 doi:10.1016/j.rpth.2025.102738.

    PMID: 40290674
  18. 18

    Case Report-Severe Hyponatremia at Birth in a Premature Infant.

    Al-Omari L, Stranberg A, Fuenmayor MF, Jain S

    Journal of mother and child 2024; (28(1)):83-86 doi:10.34763/jmotherandchild.20242801.d-24-00006.

    PMID: 39442071
  19. 19

    Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia.

    Lim CC, Siow B, Choo JCJ, et al.

    International urology and nephrology 2019; (51(6)):995-1004 doi:10.1007/s11255-019-02155-9.

    PMID: 31028561
  20. 20

    Use of Desmopressin in Hyponatremia: Foe and Friend.

    Achinger SG, Ayus JC

    Kidney medicine 2019; (1(2)):65-70 doi:10.1016/j.xkme.2019.02.002.

    PMID: 32734186
  21. 21

    Assessment and validation of a defined fluid restriction protocol in the use of subcutaneous desmopressin for children with inherited bleeding disorders.

    Mason JA, Robertson JD, McCosker J, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22(5)):700-5 doi:10.1111/hae.12949.

    PMID: 27385253
  22. 22

    Effective hemostasis in children with Von Willebrand factor defects undergoing adenotonsillar procedures.

    Diaz R, Musso M, Mahoney D

    Pediatric hematology and oncology 2021; (38(1)):25-35 doi:10.1080/08880018.2020.1806970.

    PMID: 32804010
  23. 23

    Side effects of desmopressin in patients with bleeding disorders.

    Stoof SC, Cnossen MH, de Maat MP, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22(1)):39-45 doi:10.1111/hae.12732.

    PMID: 26036844
  24. 24

    Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII.

    Shao Y, Wu W, Xu G, et al.

    Blood 2019; (134(20)):1745-1754 doi:10.1182/blood.2018886069.

    PMID: 31558466
  25. 25

    Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment.

    Hazendonk HCAM, Heijdra JM, de Jager NCB, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2018; (24(3)):460-470 doi:10.1111/hae.13451.

    PMID: 29573506
  26. 26

    Effectiveness of long-term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease.

    Rugeri L, Harroche A, Repessé Y, et al.

    European journal of haematology 2022; (109(1)):109-117 doi:10.1111/ejh.13778.

    PMID: 35438801

This page provides educational information about the DDAVP challenge test for Von Willebrand Disease. It does not replace professional medical advice. Always consult your hematologist regarding your specific testing and treatment plan.

Get notified when new evidence is published on Von Willebrand Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.